Find verified Ruxolitinib hemifumarate API manufacturers, suppliers, and distributors across the globe. Explore companies that offer high-purity Ruxolitinib hemifumarate for pharmaceutical use, along with product details, certifications, and reliable sourcing options. Compare prices, check availability, and connect directly with trusted suppliers for Ruxolitinib hemifumarate API.
Alternate Names: Jakafi, Jakavi, Opzelura,
CAS No: 2803478-47-7
PubChem CID: 168449714
Mol Formula: C38H40N12O4
Mol Weight: 728.8 g/mol
IUPAC Name: (E)-but-2-enedioic acid;(3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile
API Description: Ruxolitinib hemifumarate is used as an oral Janus kinase (JAK1/JAK2) inhibitor to treat several serious hematologic and inflammatory conditions. Used to treat myelofibrosis (a rare bone marrow cancer). Indicated for polycythemia vera in patients intolerant to hydroxyurea. Approved for graft-versus-host disease (GVHD) after stem cell transplant. Investigated and sometimes used off-label for atopic dermatitis and alopecia areata.
